Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
about
The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-AnalysisClinical impact of treatment timing for chronic hepatitis C infection: a decision modelDuplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C PatientsBarriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.
P2860
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@ast
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@en
type
label
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@ast
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@en
altLabel
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy
@en
prefLabel
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@ast
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@en
P2860
P356
P1433
P1476
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
@en
P2093
Benjamin P Linas
P2860
P356
10.1002/HEP.27220
P407
P577
2014-07-01T00:00:00Z